Index

Note: Page numbers in *italics* refer to figures, those in **bold** to tables.

ABL oncogene, 59
absolute risk, 282
access to genetic testing, 442–443
accuracy, laboratory, 317
acute lymphoblastic leukemia (ALL), detection of, 24
adduct, 53
adenocarcinomas
  characteristics of, 197
  FAP-related, 208
  intramucosal, 197
  MAP-related, 216
  *in situ*, 197
  types of colorectal, 197–198
adenomas
  characteristics of, 195
  and CRC incidence, 194
  development of, 59
  in Lynch syndrome, 213
  precancerous, 196
  screening for premalignant, 181
  sessile, 196
  tubular, 195
  tubulovillous, 196
  types of, 194–195, 195
  villous, 195
adjuvant therapy, for CRC, 206–207
adoptions, in family history, 244
adrenal cortical carcinoma (ACC), 103, 177
adrenal gland
  syndromes associated with, 454
  tumors of, 454
Adult Lhermitte-Duclos disease (LDD), 128
African Americans, cancer in, 4, 4–5, 6–7, 7
  age, 276
  and anxiety during counseling sessions, 373
  and breast cancer incidence, 153, 154
  in cancer etiology, 11
  in cancer history, 228–229
  and cancer incidence, 8
  in colorectal cancer, 191
  and inherited forms of cancer, 247–248
  alcohol use
  and breast cancer incidence, 154
  in cancer etiology, 15
  in colorectal cancer, 191
  allogeneic transplant, 43
ALPS. See autoimmune lymphoproliferative syndrome
American Board of Genetic Counselors, on ethics, 411
American Cancer Society (ACS), 291
  on colon cancer screening, 199, 200
  guidelines for breast cancer of, 162
  preventive guidelines for CRC of, 200
American Joint Committee on Cancer Staging (AJCCS), 34
American Society of Clinical Oncology, 442
American Society of Human Genetics, 436
ampulla of Vater
  syndromes associated with, 454
  tumors of, 454
Amsterdam II criteria
  for HNPCC, 106, 107
  for Lynch syndrome, 214

anaplastic tumors, 33
anatomical features, of malignant cells, 47–48
anemias, syndromes associated with, 452. See also Diamond-Blackfan anemia; Fanconi anemia
aneuploidy, in oncogene activation, 63
anger, client’s response as, 358–359
angiogenesis, process of, 51
anonymous testing, request for, 434
anxiety
baseline, 372
client’s response as, 359
test results and, 342
APC genetic testing, 91, 401
APC mutation, in FAB, 209
apoptosis, defined, 51
areola, of breast, 152, 152, 153
Arimidex (aromatase inhibitor), 169
Aromasin (aromatase inhibitor), 169
ascending colon, anatomy of, 188, 188
Ashkenazi Jewish ancestry, 173, 232
and Bloom syndrome, 83
and breast cancer incidence, 155–156
FAP in, 93
and HBOCS, 84, 85
Asian women, cancer in, 6
ataxia telangiectasia (A-T), 75–77
cancer risks of, 76
clinical features of, 76
diagnostic criteria for, 76
resources for, 77
syndrome subtypes for, 77
atomic bombings, Hiroshima or Nagasaki, 158
attentiveness, practice attached, 422
authority, justice and, 416
autoimmune lymphoproliferative syndrome (ALPS), 77–78
cancer risks associated with, 77
clinical features of, 78
diagnostic criteria for, 77–78
resources for, 78
syndrome subtypes of, 78
autologous transplant, 43
autonomy
client, 421–422
lack of, 433
principle of, 412–414
autopsy report, in cancer history, 241
bacteria, carcinogenicity of, 15–16, 16
Bannayan-Riley-Ruvalcaba (BRR) syndrome. See PTEN hamartoma syndrome
barium enema, for CRC, 202
basal cell nevus syndrome. See nevoid basal cell carcinoma syndrome
Bean syndrome. See blue rubber bleb nevus syndrome
Beckwith-Wiedemann syndrome (BWS), 71, 78–80
cancer risks with, 79
clinical features of, 80
diagnostic criteria for, 79–80
resources for, 80
behavioral problems, in cancer history, 230
beneficence, principle of, 415
benign tumors
hormones excreted by, 32
location and size of, 31–32
best-case/worst-case scenarios, 334–335
Bethesda criteria, for Lynch syndrome, 106, 107, 214
BHDS. See Birt-Hodge-Dubé syndrome
biases, in risk communication, 286
bile duct syndromes associated with, 454
tumors of, 454
billing policies, of genetic testing laboratories, 317
biochemistry, of malignant cells, 48
bioethics
ethics in, 409–410, 410, 411
principle-based, 412–416, 414
biological therapy
for breast cancer, 169–170
for CRC, 206
biology, cancer
carcinogenesis, 52–59, 54, 56, 57, 58
epigenetic mechanisms, 70–73
malignant cells, 47–52, 48, 49
oncogenes, 59–64, 60, 64
tumor suppressor genes, 64–70, 66, 68, 69
biopsy
of breast mass, 165
for CRC, 203
to diagnose cancer, 25
sentinel node, 170
birth certificate, 244
birth defects, in cancer history, 230
Birt-Hodge-Dubé syndrome (BHDS), 80–82
cancer risks with, 80–81
clinical features of, 81
diagnostic criteria for, 81
resources for families, 82
bladder syndromes associated with, 460
tumors of, 460
bladder carcinoma, RAS oncogene in, 62
blastomas, 30
blood tests, for CRC, 203
blood vessels
of colon, 190
of rectum, 190
Bloom syndrome (BS), 82–83
cancer risks with, 82
clinical features of, 83
diagnostic criteria for, 82–83
resources for, 83
Bloom syndrome (BS) Registry, 82
blue rubber bleb nevus syndrome (BRBNS), 83–84
cancer risks with, 83–84
clinical features of, 84
diagnostic criteria for, 84
resources for, 84
BMPRIA mutations, 98, 99
body mass index (BMI), and CRC, 194
bone
syndromes associated with, 453
tumors of, 453
bone marrow toxicity, chemotherapy associated with, 41
bone marrow transplantation, 42–43
boundaries
establishing, 405
respecting, 386–387
brain
syndromes associated with, 451
tumors of, 451
brainstorming
in decision making, 334–335
to resolve ethical dilemmas, 428
brain tumors
FAP-related, 208
LFS-related, 178
BRCA mutations, 175, 304, 346
BRCA1/2 mutations, 85, 86, 173
BRCA1/2 testing, 335, 404
BRCA1-related tumors, 172
BRCA2-related tumors, 172
breast
atypical hyperplasia in, 154–155, 155
basic anatomy of, 151–153, 152
syndromes associated with, 457
tumors of, 457
breast cancer
case examples, 304, 304–306
case history, 258–262, 262
diagnosing of, 164–166, 167
family history for, 232, 234
follow-up questions about, 233
global incidence of, 10
in HBOCS, 172
HDGC-related, 175
inflammatory breast, 161
intraductal, 159
invasive, 159–161
LFS-related, 177
PHS-associated, 182–183
PJS-related, 180
preventive guidelines for, 163
recurrent, 171
risk factors for, 153–158, 154, 154, 155, 184
screening and prevention guidelines for,
162, 162–164, 163
staging of, 170–171
syndrome of, 171–175, 172
treatment for, 166, 168–171
warning signs of, 163, 163
breast conditions, benign, and breast cancer incidence, 154–155, 155
breast lesions, benign, 158–159
breast-ovarian cancer syndrome, hereditary (HBOCS), 84–87, 171–172, 172, 303
cancer risks with, 85
case example, 347, 347–349
case history, 258–262, 262
clinical features of, 86
counseling client at low risk for, 290, 290
diagnostic criteria for, 85–86
family history assessment for, 173
incidence of, 171–172, 172
management of, 173–175, 174
resources for, 87
syndrome subtypes of, 86
tumor types, 172–173
breast tissue, anatomy of, 151
BWS. See Beckwith-Wiedemann syndrome
café au lait spots (macules), in NFI, 118
Canale-Smith syndrome. See autoimmune lymphoproliferative syndrome
cancer
anxiety producing types, 373
autosomal dominant pattern of, 248
common forms of, 25, 26
diagnosis of, 23–27, 24, 26
etiology of, 10–11, 11, 12
modifiable risk factors, 12, 13–18, 14, 16, 17
nonmodifiable risk factors, 11–13, 12
excess of multifocal or bilateral, 248
cancer (cont’d)
excess of multiple primary, 248–249
LFS-related, 178
primary, 30–31
prior experiences with, 373
rare, 248
recurrence of, 31
sporadic forms of, 251
terminology
cell type, 30
site of origin, 27
tissue type, 27, 27–30
cancer cells
features of, 47–48, 48, 49
functional properties of, 48–52, 50
cancer clusters, 19–20, 251
cancer genetic counselors. See also genetic counselors
ethical, 421, 421–423
moral character traits of, 418, 418
cancer genetics, advances in, 421
cancer risk counselors, 357
cancer story, in genetic counseling session, 23. See also stories
cancer syndromes. See also hereditary cancer syndromes
counseling about likelihood of,
290, 290, 292, 292–293, 293, 295, 296
identification of, 222–223
in risk communication, 283
candor, in risk communication, 288
carneogenesis
stages of, 53–57, 54, 56, 57
two-hit model of, 57
Vogelstein’s multistep process of, 58, 58–59
carcinogens
broad exposures to, 251
in cancer history, 232
in digested food, 191
environmental, 232
exposures to, 20–21
in family business, 251
identification of, 13–14
job-related, 232
carcinoid tumors, in MEN1, 113
carcinomas
defined, 28
by organ system, 28
cardiovascular system
syndromes of, 450
tumors of, 450
caretaker genes, 65, 66, 66
caring, ethics of, 420
caring theorists, 420
Carney complex (CNC), types I and II, 87–89
cancer risks with, 87
clinical features of, 88
diagnostic criteria for, 87–88
resources for, 89
Carney-Stratakis syndrome. See paraganglioma-pheochromocytoma syndrome
carrier test, purpose of, 313
case examples
breast cancer, 304, 304–306
client family with FAP, 298–301, 299
client with melanoma, 301–303, 302
DCIS, 403–405
genetic counseling
cancer etiology in, 18–21
about DCIS, 403–405
about FAP, 400–403
VHL gene mutation, 405–407
of genetic testing, 346–356
HBOCS, 347, 347–349
LFS, 352–356, 354
Lynch syndrome, 349–352, 350
case histories
breast cancer, 258–262, 262
Lynch syndrome, 262–266, 264, 265
paraganglioma-pheochromocytoma syndrome, 255–258, 257, 259
CDH1 mutations, 297, 298
CDKN2A mutation, 110
cell cycle
and cancer predisposition genes, 49
checkpoints, bypassing, 50
regulators, 61
cell proliferation, 50, 50
cellular differentiation, 33, 34, 48–50
central nervous system (CNS) syndromes associated with, 451
tumors of, 451
cerebellar dysplastic gangliocytoma, PHS-related, 183
cerebro-oculo-facial-skeletal syndrome (COFS), 144
certainty, in risk communication, 283
cervix
syndromes associated with, 457
tumors of, 457
character traits, moral, 418, 418
check-ins, in risk communication, 286
chemotherapy
  action of, 41
  for breast cancer, 169, 170, 171
  for CRC, 205–206
  cytotoxic agents, 42
  first clinical use of, 42
  goal of, 41
  hormonal agents, 42
  side effects of, 41
children
  cancer incidence in, 4, 4
  mortality rates for, 4
  testing of, 440–441
Chompret’s criteria, for TP53 testing, 103
choroid plexus carcinoma, 103
chromosomal anomalies, in cancer etiology, 13
chromosome 17p13, TP53 gene on, 67–68, 68
  chromosome rearrangement, and
  inactivation of tumor suppressor genes, 67
chronic medical conditions, in cancer etiology, 12–13
circulatory system, 55
  syndromes associated with, 452
  tumors of, 452
C-KIT mutations, 97
clients
  age of, 311
  assessing interest in testing of, 321–322
  cancer status of, 310
  collecting family history from, 242
  deceased, ownership of test results for, 439–440
  determining eligibility of, 309–311
  a priori risks for, 311
  psychosocial features of
  358
  common emotional responses, 357–362,
  coping strategies, 362–371, 364
  risk perception of, 274, 274–278
  test results for, 323
  understanding genetic tests of, 324
  with emotional vulnerability, 438–439
  client understanding, in risk communication, 281
  clinical certification, requirements for, 317
  clinical examination of breast, 164
  for CRC, 202
  clinical laboratories, 316
  clinical record, pedigree in, 225. See also
  pedigree
Cockayne syndrome (CS), 129
  code of ethics, of NSGC, 412, 429
  coercion/pressure for genetic testing, 432–433
  cognitive functioning, and risk perception, 274
  colectomy, 205, 298
  in classic FAP, 209–210
  prophylactic, 211, 215
colleagues, as ethical resource, 429
colon
  anatomy of, 187–191, 188, 188, 190
  syndromes associated with, 454
  tumors of, 454
  colon cancer. See also familial adenomatous
  polyposis
  JPS-related, 211–212
  Lynch syndrome-related, 216
  Vogelstein’s model of, 58, 58–59
  colonization, 57
colonography, computed tomography, 202
colonoscopy, 199, 211
  procedure, 201
  side effects of, 201
coloradocarcin (CRC)
  diagnosing, 201–203, 204
  etiology of, 12–13
  intramucosal, 197
  invasive, 197–199
  Lynch syndrome associated with, 106–107, 108
  metastases in, 203
  personal history of, 194
  PHS-related, 183
  PJS-related, 180
  recurrent, 207
  risk factors for, 191–194
  risk of, 200–201
  screening and prevention guidelines for, 199–201, 200, 201
  syndromes, 206, 207–217, 208, 210, 212, 215, 218
  treatment by stage, 206–207
  treatment of, 204–206
  warning signs of, 199, 201
  colorectal lesions, benign, 194–197, 195
  colorectal walls, anatomy of, 189
  colored eco-genetic relationship map
  (CEGRM), 392–394, 393, 394, 395
  colostomy, 205
  comfort, for cancer counseling clients, 361
  communication, family, 378. See also risk communication
comparisons, in risk communication, 280
compassion, of genetic counselors, 418
competency, autonomy and, 412
competing rights of family members, 439
computed tomography (CT) colonography, 202
confidentiality
autonomy and, 413–414, 414
of cancer pedigree, 236
in genetic testing, 321, 436–438
respecting client, 422
conflict of interest, 433
congenital hypertrophy of retinal pigment epithelium (CHRPE), 209
connective tissue
of breast, 152
syndromes associated with, 453
tumors of, 453
conscientiousness, of genetic counselors, 418
constitutional mismatch repair-deficiency (CMMR-D) syndrome, 108
control, loss of, 361
coping resources, in psychological assessment, 336
coping strategies, 362–371, 364
accepting responsibility, 363–364
anxious preoccupation, 364
cognitive avoidance, 365
compulsions, 469
confrontive, 365
denial, 365–366
development of, 363
displacement, 366
distancing, 367
escape-avoidance, 367
of families, 376
fatalism, 367
fighting spirit, 367
holistic practices, 370–371
humor, 368
intellectualism, 368
magical thinking, 368
obsessions, 469
planning, 469
positive reappraisal, 469
projection, 369–370
in psychosocial assessment, 382, 382
rationalization, 370
regression, 370
relying on social support, 370
seeking approval from caregivers, 371
self-controlling, 371
spiritual, 370–371
stoic acceptance, 371
coping styles, and risk perception, 275
costs, of genetic testing, 319–321
counseling sessions
elements of, 267–271, 268
impact of clients’ fears on, 371–374, 372
risk information in, 273
setting tone for, 226
counseling visits
results disclosure in, 337–338
for testing program, 318
types of, 271–272, 272
counselor, empathy of, 238
counselor-client relationship, basis of, 412
countertransference, in genetic counseling, 388
Cowden syndrome. See PTEN hamartoma syndrome
cryotherapy, 44
cues
in psychosocial genetic counseling, 384
in risk communication, 285
cultural differences, in risk communication, 287
culture. See also ethnicity
and cancer-related fears, 374
and genetic testing, 324
and risk perception, 274–275
customer service, of genetic testing laboratories, 318
cystosarcoma phyllodes, 158, 161
cysts, breast, 158
daily activities, impact of cancer fears on, 374–375
data, in risk communication, 281–282
dates, in cancer history, 228–229
death, leading causes of, 5, 5, 8, 10, 10
death certificate, in cancer history, 241
deceased clients, ownership of test results for, 439–440
decision making
assisting client with, 334–335
autonomy and, 412–413
and ethical dilemmas, 427
and ethical principles, 425
goals of, 333
impact of cancer-related fear on, 375
respecting client’s, 422
dedifferentiation, 49
deletion
and inactivation of tumor suppressor
genes, 66
in oncogene activation, 63
deletion 5q22 syndrome, 92
demographic data, on genogram assessment
tool, 390
denial, versions of, 365–366
Denys-Drash syndrome (DDS), 142. See also
Wilms tumor
depression, test results and, 342
descending colon, anatomy of, 188, 188
descriptions, qualitative, in risk
communication, 280
desmoid disease, hereditary. See familial
adenomatous polyposis
desmoid tumors, 91, 92, 209, 211
detection, cancer, 23–24
common warning signs, 24, 24
evasive premalignant cells in, 25
imperfect screen methods in, 25
lack of warning signs in, 24
diabetes, in colorectal cancer, 191
diagnosis
in cancer history, 227–228
client’s misunderstanding of, 245
in risk communication, 283
diagnostic test, purpose of, 313
Diamond-Blackfan anemia (DBA), 89–90
cancer risks with, 89
clinical features of, 90
diagnostic criteria for, 89–90
resources for, 90
diet
in cancer etiology, 15
in cancer incidence, 11, 11
in colorectal cancer, 191
diethylstilbestrol (DES), cancers associated
with, 18
differentiation, 48–50
digital rectal exam, 202
disability, fear of, 359
discernment, of genetic counselors, 418
disclosure, results. See also test results
client reactions to, 341–343
and client’s needs, 338–339
follow-up counseling visit for,
271–272, 272
follow-up for, 340–341
of genetic tests, 319
mode of, 337–339
strategies for, 339–341
topics covered during, 338
disfigurement, fear of, 359
displacement, as coping strategy, 366
DNA, role of adduct in, 53
DNA analysis, in pretest counseling, 325–327
DNA methylation, 71–72
DNA repair genes, 49, 51, 68–70, 69
DNA sequencing, 36, 37
DNA testing, 321
donor eggs/sperm, in family history, 244
double contrast barium enema, for CRC, 202
Down syndrome, cancer associated with, 13
ductal carcinoma in situ (DCIS), 159, 403–405
ducts, of breast, 152, 152
duties, in bioethics, 410
duty to recontact, 438
duty to warn, 436–438
dying, fear of, 359–360
dysplastic nevus syndrome. See melanoma,
cutaneous malignant
dysphasia, fear of, 359
ear
syndromes associated with, 456
tumors of, 456
ectoderm, 27, 28
embryo
testing, for hereditary cancers, 441–442
tumor origins in, 27, 27
EMG syndrome. See Beckwith-Wiedemann
syndrome
emotional state, assessing, 226, 336
emotional vulnerability, clients with, 438–439
emotions
anger, 358–359
anxiety, 359
common emotional responses, 357–362,
358
fear of disability, 359
fear of disfigurement, 359
fear of dying, 359–360
grief, 360, 360
guilt, 360–361
and interest in testing, 323
loss of control, 361
in psychosocial assessment, 379, 379–380,
381
in psychosocial genetic counseling, 386
resiliency, 361
in risk communication, 288
in risk perception, 275
sadness, 361–362
shame, 360–361
empathy, in psychosocial genetic counseling,
383, 383–384
encouragement, for cancer counseling clients, 361
endocrine system
  syndromes associated with, 454
tumors of, 454
endoderm, 27, 28
endolymphatic sac tumors (ELSTs), 137, 138
endometrial cancer
  with Lynch syndrome, 105
  screening for, 216
endoscopy
  indications for, 216, 217
  procedures, 297
ENG gene, 99
environmental pollution, cancer etiology
  associated with, 18
enzymes, of cancer cells, 51
EPCAM gene, 351
EPCAM (TACD1) gene, 214
epidemiology, cancer, statistics in, 1–10, 3, 4, 4–10
epigeneric mechanisms
  DNA methylation, 71–72
  genomic imprinting, 70–71
  epigenetic silencing, in inactivation of tumor suppressor genes, 67
equality, justice and, 416
Erin Brockovich (film), 19
esophagus
  syndromes associated with, 455
  tumors of, 455
ethical codes, 412, 429
ethical dilemmas
  anonymous testing, request for, 434
  children, testing of, 440–441
  clients with emotional vulnerability, 438–439
  competing rights of family members, 439
  conflict of interest, 433
  duty to recontact, 438
  duty to warn, 436–438
  embryo testing for hereditary cancers, 441–442
  inadequately understood consent for genetic testing, 432
  incomplete consent for genetic testing, 431–432
  lack of autonomy, 433
  pressure/coercion for genetic testing, 432–433
  resolving, 423
  evaluation for, 425–429, 426
  getting help with, 429–431, 430
  upholding principles, 424–425
strategies for dealing with, 421
test results, for deceased clients,
  ownership of, 439–440
test results, omitting from medical record, 435
test results, undisclosed, dispensation of, 435–436
unauthorized testing, 433–434
unintended/sensitive genetic information, 436
ethical principles, opposing, 427
ethics
  of caring, 420
  introduction to, 409–410, 410, 411
  virtue, 416–420, 418
ethnicity
  and breast cancer incidence, 155
  in cancer etiology, 11–12
  in cancer history, 232
  and cancer-related fears, 374
  and cancer survival rates, 6–8, 7
  and colorectal cancer incidence, 192
  incidence rates and, 4, 4–5
  mortality rates and, 6–8, 7
  and risk perception, 274–275
  events, and genetic testing decisions, 322–323
Ewing’s sarcoma, 30
experience
  in risk communication, 287–288
  and risk perception, 276–277
eye
  syndromes associated with, 456
  tumors of, 456
  in xeroderma pigmentosum, 144
face
  syndromes associated with, 456
  tumors of, 456
facts, in risk communication, 282
fallopian tubes
  syndromes associated with, 457
  tumors of, 457
familial adenomatous polyposis (FAP), 90–93, 109, 206, 208
  attenuated, 90, 92
  cancer risks with, 90–91
  case examples of clients with, 298–301, 299
  clinical features of, 92
  diagnostic criteria for, 91–92
  family history for, 209
genetic counseling for, 400–403
management of, 209–211, 210
resources for, 93
syndrome subtypes for, 92–93
tumor types, 208–209
familial atypical mole melanoma (FAMM)
syndrome, 303. See also melanoma, cutaneous malignant
familial cluster of cancer, 250–251
familial medullary thyroid carcinoma
(FMTC). See also multiple endocrine
neoplasia, type 2
clinical criteria for, 114
syndrome, 113
families
communication about cancer of, 378
coping strategies of, 376
effect of genetic information on, 375–378,
376
and genetic testing, 332–333
interest in testing of, 322
obligations of, 377
relationships within, 377
roles of, 377
stories of, 377
and test results of client, 344–345
family dynamics
cancer and, 242–243
pedigree indicating, 225–226
family events, on genogram assessment tool, 391
family history
analysis of, 237
and breast cancer incidence, 156
collection of, 200–203
collecting, 222, 232–238, 233–235
and colorectal cancer incidence, 192, 192
in counseling session, 269
as counseling tool, 238–239
different cancer syndromes in, 224
and existing family relationships, 238
false information in, 245–246
in HBOCS, 173
in HDGC, 176
incomplete, 242–243
in JPS, 212
in LFS, 178
in Lynch syndrome, 214
in MAP, 217
in PHS, 183
in PJS, 181
questionnaire for, 239
unavailable information for, 243–245
family interactions, and risk perception, 275
family members. See also relatives
competing rights of, 439
in risk assessment, 291, 294, 296–297
family relationships, on genogram
assessment tool, 391–392, 393
family stories, 226
FANC-A gene, 94
Fanconi anemia, 93–95
cancer risks with, 94
clinical features of, 94
diagnostic criteria for, 94
resources for, 95
syndrome subtypes for, 94–95
fear, in psychosocial assessment, 382
fecal immunochemical test (FIT), 202
fecal occult blood test (FOBT), for CRC, 202
Femara (aromatase inhibitor), 169
fibroadenomas, of breast, 158
fibrocytic breast disease, 155
fibrous tissue, of breast, 152
fidelity, of genetic counselors, 419
figures, in risk communication, 282
five-year survival rates, 6–8, 7
FLCN genetic analysis, 81
flexibility, in risk communication, 284
fluorescence in situ hybridization (FISH), 36
follow-up
in cancer history, 229
planning for, 270
food contaminants, cancers associated with, 18
founder mutation testing, in pretest
counseling, 327–328
5-FU (fluorouracil), 205
Frasier syndrome (FS), 142. See also Wilms
tumor
fumarate hydratase (FH) gene, 100
functioning level, on genogram assessment
tool, 390–391
Gail model, for lifetime risk of breast cancer,
156–157
gallbladder
syndromes associated with, 455
tumors of, 455
gambler’s odds, in risk communication, 279
Gardner’s syndrome. See familial
adenomatous polyposis
gastrectomy, prophylactic, 176
gastric cancer, 10, 105. See also Lynch
syndrome
gastric cancer, diffuse, 175, 176
gastric cancer, hereditary diffuse (HDGC), 95–96, 171, 175–176

cancer risks with, 95
clinical features of, 96
diagnostic criteria for, 95–96
family history assessment for, 176
incidence of, 171, 175
management recommendations for, 176, 177
pedigree of client at risk for, 296
resources for, 96
tumor types, 175–176
gastrointestinal (GI) system
PJS-related tumors of, 180
syndromes associated with, 454–455
tumors of, 454–455
gastrointestinal stromal tumor (GIST), 197, 198–199, 237
gastrointestinal stromal tumor (GIST), familial, 97–98
cancer risks with, 97
clinical features of, 97
diagnostic criteria for, 97
resources for, 98
gatekeeper genes, 65, 66

gender
and anxiety during counseling sessions, 373
and breast cancer incidence, 156
in cancer etiology, 12
and colorectal cancer incidence, 192
gender differences, in global cancers, 8, 8
gene amplification
in inactivation of tumor suppressor genes, 67
in oncogene activation, 63
gene silencing
epigenetic, 70–73
mechanisms, 72–73
gene therapy, 44
Genetic Alliance, 398
genetic analysis, 35
genetic counseling, See also case examples
effective psychosocial, 383, 383
active listening in, 385, 385
asking questions in, 385–386
clients’ rationale in, 386
emotional expression in, 386
empathy in, 383
helping client with decisions and actions, 389–390
monitoring client reactions in, 387
professionalism in, 388–389
resistant clients in, 387
respecting boundaries in, 386–387
verbal and nonverbal cues in, 384
ethical dilemmas in, 431–442
pretest
about accuracy and limitations, 329–330
about making decisions, 333, 333–335
possible results, 325–329
psychological assessment for, 335–337
about risks and benefits, 330, 330–333, 331
use of pedigrees in, 225
genetic counselors, ethical guidelines for, 429, 430. See also cancer genetic counselors
Genetic Insurance Nondiscrimination Act (GINA) (2008), 331, 331
genetic predisposition
and breast cancer incidence, 156
and colorectal cancer, 193
inheritance of, 225
genetics
cancer, 421
of malignant cells, 48, 49
genetic testing. See also disclosure; test results
access to, 442–443
anonymous, request for, 434
arranging for, 269
choosing laboratory, 315–318
client’s interest and readiness, 321–325
determining client eligibility, 309–311
explaining testing process, 318–321, 319
selecting right tests, 311–314, 312
selection challenges, 314–315
clinically available, 312
consent for, 431–433
cost of, 319–321
counseling visit for, 271, 272
determining need for, 224
discussing with client, 321
ethical dilemmas in, 431–442
in family history, 241
follow-up to, 345–346
justice, issues of, in, 442–443
limitations of, 314–315
logistics of, 319
post-results discussions, 343–346
in risk assessment, 291, 294, 297
timing issues for, 323–324
unauthorized, 433–434
genogram assessment tool, 390–392, 391, 392
genomic imprinting, 70–71
genomic instability, 52
genomic rearrangement testing, in pretest counseling, 328–329
germ cell	syndromes associated with, 457
tumors of, 457
goals, for counseling sessions
client’s, 268–269
counselor’s, 268
Gorlin syndrome. See nevoid basal cell carcinoma syndrome
grading of tumors
based on cell differentiation, 33, 34
histological, 32–33, 33
Gray units (Gy), 40
grief, 360, 360
group, cancer risk support, 399
group counseling, 20
growth factor receptors, 61
growth factors, 60
guaiac test, for CRC, 202
guilt, 360–361
hair, conditions associated with, 459
hamartomas
of breast, 158
characteristics of, 196
PHS-related, 183
PJS-related, 180
screening for, 181
HBOCS. See breast-ovarian cancer syndrome, hereditary
head and neck	syndromes associated with, 456
tumors of, 456
heart
syndromes of, 450
tumors of, 450
*Helicobacter pylori* infection, 96, 175
hemorrhagic telangiectasia (HHT), 99
Herceptin (trastuzumab), 170
hereditary cancer syndromes
abbreviations for, 449–450
ataxia telangiectasia, 75–77
autoimmune lymphoproliferative syndrome, 77–78
Beckwith-Wiedemann syndrome, 78–80
Birt-Hogg-Dubé syndrome, 80–82
Bloom syndrome, 82–83
blue rubber bleb nevus syndrome, 83–84
breast-ovarian cancer syndrome, hereditary, 84–87
Carney complex, types I and II, 87–89
case histories for, 255–266, 257, 259, 262, 264
cutaneous malignant melanoma, 109–111
Diamond-Blackfan anemia, 89–90
embryo testing for, 441–442
and environmental risk factors, 249–250
familial adenomatous polyposis, 90–93
familial neuroblastoma, 116–117
Fanconi anemia, 93–95
gastric cancer, 95–96
gastrointestinal stromal tumor, 97–98
hereditary papillary renal cell carcinoma, 130–131
hereditary retinoblastoma, 131–133
juvenile polyposis syndrome, 98–100
leiomyoatosis renal cell cancer, 100–101
Li-Fraumeni syndrome, 101–104
Lynch syndrome, 105–109
MEN1, 111–113
MEN2, 113–115
multiple mutations in, 314
MYH-associated polyposis, 115–116
neurofibromatosis, type 1, 118–119
neurofibromatosis, type 2, 119–121
nevoid basal cell carcinoma syndrome, 121–123
nonmalignant features of, 249, 249
oncogenes associated with, 62
paraganglioma-pheochromocytoma syndrome, 123–125
pedigree of family at low risk for, 254, 254
Peutz-Jeghers syndrome, 125–127
PTEN hamartoma syndrome, 127–130
Rothmund-Thomson syndrome, 133–134
testing for, in children, 440–441
and 3-2-1 rule, 250
tuberous sclerosis complex, 134–136
tumor suppressor genes associated with, 66
von Hippel-Lindau syndrome, 137–139
Werner syndrome, 139–141
Wilms tumor, 141–143
xeroderma pigmentosum, 143–145
hereditary mixed polyposis. See juvenile polyposis syndrome
hereditary nonpolyposis colorectal cancer (HNPCC), 92
heredity, in cancer etiology, 12
heuristics, and risk perception, 275–276
histology, 32–33
history, cancer
  analysis of, 237
  classification of, 250–251
  client fabrication in, 245–246
  historian for, 236–238
  interpreting, 246–250
  purposes of, 222–226
  survey of, 236–238

history, patient, elements of, 227–232, 228.
  See also family history; personal history

H19 genes, 79
HNPPCC. See Lynch syndrome
Hodgkin’s disease, 30
hope, of cancer counseling clients, 361
hormonal therapy, 42, 169, 170, 171
hormones, and breast cancer incidence, 157
hospitals
  ethical review boards of, 429–430
  ethics and, 411
hospitals summary notes, in cancer history, 241
hydatidiform mole, 70
hysterectomy, indications for, 216

ideals, in bioethics, 410
identity, sense of, 362
IGF2 genes, 79
I1307K mutation, 93
images, visual, in risk communication, 283–284
imaging studies, to diagnose cancer, 25
immunodeficiency, syndromes associated with, 452
immunohistochemistry (IHC) test, in Lynch syndrome, 107, 108
immunotherapy, 44–45
imprint organizing center, 72
inadequately understood consent for genetic testing, 432

incidence
  cancer
    and age, 8
    in children, 4, 4
    common forms of, 2, 3
    gender differences in, 2, 3
    geography of, 5
    global, 8–10, 8–10
    in U.S., 2–5, 3, 4, 4
    use of term, 1–2
  incomplete consent for genetic testing, 431–432
  industrialized countries, and cancer incidence, 8, 10, 10
  infancy, juvenile polyposis of, 99
  infectious agents, in cancer etiology, 15–16, 16
  infiltrating ductal carcinoma, of breast, 160
  infiltrating lobular carcinoma, of breast, 160
  inflammatory bowel disease (IBD)
    and colorectal cancer, 193
    pseudopolyps identified with, 196
information
  on Internet, 398
  and risk perception, 276
  informed consent
    autonomy and, 413
    for genetic testing, 318–319, 319
    as process, 423
  inherited cancer syndromes, features of, 246–247, 247
  initiation, of carcinogenesis, 53, 54
  insertions, in oncogene activation, 63
  insurance coverage, of genetic testing, 315, 320
  integrity, of genetic counselors, 419
  International Agency for Research on Cancer (IARC), 14
  International Gastric Cancer Linkage Consortium, 96
  International Union Against Cancer (IUAC), 34
  Internet, information provided by, 398
  interview, family history, 226. See also family history
  intestinal tract. See also gastrointestinal system
    syndromes associated with, 455
    tumors of, 455
  invasive procedures, to diagnose cancer, 25
  inversions, in oncogene activation, 62–63
  investigational review board (IRB), hospital, 425
  isolation, sense of, 362

justice
  issues of, in genetic testing, 442–443
  principle of, 415–416
  juvenile polyposis, 196
  juvenile polyposis syndrome (JPS), 98–100, 207, 211
  cancer risks with, 98
  clinical features of, 99
diagnostic criteria for, 98–99
family history for, 212
incidence of, 211
management of, 212, 212–313
resources for, 100
syndrome subtypes for, 99
tumor types, 211–212

Kaposi’s sarcoma, 30
kidney
syndromes associated with, 460
tumors of, 460
kindness, of genetic counselors, 419
Klinefelter syndrome, cancer associated with, 13
Knudson’s model of retinoblastoma, 57, 58

laboratory
choosing, 315–318
clinical, 316
research, 316–317

Lamb syndrome. See Carney complex, types I and II
landscaper genes, 66
language, in risk communication, 283
large-cell calcifying Sertoli cell tumor (LCCST), 88
larynx
syndromes of, 450
tumors of, 450
laser therapy, 44
leader(s), of cancer risk support groups, 399
learning problems, in cancer history, 230
leiomyoatosis renal cell cancer, hereditary (HLRCC), 100–101
cancer risks with, 100
case example, 352–356, 354
case history, 262–266, 264, 265
clinical features of, 101
diagnostic criteria for, 102, 102–103
family history assessment for, 178
incidence of, 177
management of, 179, 179–180
resources for, 104
syndrome subtypes for, 104
testing for, 441
tumor types, 177–178
linitis plastica, 175
listening, active, in effective psychosocial genetic counseling, 385, 385

liver
syndromes associated with, 455
tumors of, 455
lobular carcinoma in situ (LCIS), 159
lobules, of breast, 152, 153
low penetrant RB, 132
lumpectomy, in DCIS, 170
lung
syndromes of, 450
tumors of, 450
cancer risks with, 105–106
case example, 352–356, 354
cancer history, 262–266, 264, 265
clinical features of, 104
diagnostic criteria for, 102, 102–103
family history assessment for, 178
incidence of, 177
management of, 179, 179–180
resources for, 104
syndrome subtypes for, 104
testing for, 441
tumor types, 177–178

lymphatics
of colon, 190
of rectum, 190
lymphatic system, 55
syndromes associated with, 452
tumors of, 452
lymph nodes, biopsy of, 165
lymphomas, 30, 198
ataxia telangiectasia associated with, 76
by organ system, 29
syndromes associated with, 452
lymph vessels, of breast, 152, 153
Lynch syndrome, 105–109, 193, 213
cancer risks with, 105–106
case example, 349–352, 350
case history, 262–266, 264, 265
Lynch syndrome (cont’d)
clinical features of, 108
diagnostic criteria for, 106–108
family history in, 214
incidence of, 213
management of, 215, 215–216
pedigrees of client at risk for, 292, 292, 293
resources for, 109
syndrome subtypes for, 108–109
tumor types, 213–214

macrocephaly, in PHS, 128
malignant cells, features of, 47–48, 48, 49
mammography, 164, 179
Manchester Criteria, for NF2, 120
manufacturing, carcinogenic agents in, 17
mastectomy
indicators for, 168
nipple-sparing, 398
prophylactic, 180, 184
types of, 168
MDM2 gene, 104
medical care practices, impact of cancer-related fear on, 375
medical care providers, professional obligations of, 417
medical conditions, in cancer history, 230, 231
medical management
following test results, 344
and genetic testing, 332
as option, 270
medical records
importance of, 421
lost, 243
obtaining, 239
omitting test results from, 435
Medicare, genetic testing covered by, 320
medicinal drugs, cancers associated with, 18
medicine
ethics and, 411
mistakes in, 417
medullary carcinoma, of breast, 160
medullary thyroid carcinoma, cancer staging of, 35, 35
medulloblastomas, 122
melanoma, cutaneous malignant (CMM) syndrome, 109–111
cancer risks with, 109–110
clinical features of, 110–111
diagnostic criteria for, 110
resources for, 111
melanoma-astrocytoma syndrome, 109

melanomas, 198
case examples of client with, 301–303, 302
defined, 29
ocular, 110
MEN1. See multiple endocrine neoplasia, type 1
MEN2. See multiple endocrine neoplasia, type 2
mental health history, in psychosocial assessment, 380, 380–381
medical professionals, establishing alliances with, 396
mental health referral, making, 394–398, 396, 397
mesoderm, 27, 28
metabolism, of cancer cells, 51
metastasis, 30
of cancer cells, 52
in carcinogenesis, 54, 55, 56, 57, 57
defined, 31
metastatic cancer, of unknown origin, 33
methylation, DNA, 70, 71–72
microcalcifications, of breasts, 159
microsatellite instability-high tumor (MSI), and colorectal cancer, 193–194
migration, of cancer cells, 52
mining, cancer etiology associated with, 18
minors
emancipated, 440
testing of, 440–441
mitoycin C chromosome stress test, 94
mitotic nondisjunction, and inactivation of tumor suppressor genes, 67
mitotic recombination, in inactivation of tumor suppressor genes, 67
mixed polyposis syndrome, hereditary (HMPS), 99
MLH1 gene, 194, 214
MOAB 17-1A, 206
molecular studies, examples of, 36, 37
monitoring client
in psychosocial genetic counseling, 387
Montgomery’s glands, 153
morality, common, 410
mortality rates, 5–8, 5–7
age and, 5, 5
for children, 4, 5, 5
ethnicity and, 6–8, 7
gender and, 6
metastasis, 57
for selected cancers, 6, 7
mouth
syndromes associated with, 457
tumors associated with, 457
MRI, breast, 164
MSH2 gene, 214
MSH6 gene, 214
MSI test, in Lynch syndrome, 107, 108
mucinous carcinoma
adenocarcinoma, 197
of breast, 160
mucosa, of colorectal walls, 189, 190
Muir-Torre syndrome, 31, 105, 108
multiple endocrine neoplasia, type 1 (MEN1)
syndrome, 81, 111–113
cancer risks with, 111
clinical features of, 112–113
diagnostic criteria for, 112
resources for, 113
multiple endocrine neoplasia, type 2 (MEN2)
syndrome
cancer risks with, 113
clinical features of, 114
diagnostic criteria for, 114
resources for, 115
syndrome subtypes for, 114–115
multiple endocrine neoplasia type 2B
(MEN2B), 113
Münchausen syndrome, 246
muscularis externa, of colorectal walls, 189, 190
mutation, 50. See also specific mutations
and inactivation of tumor suppressor
genes, 66
initiating, 53
and signaling networks, 52
somatic, 53
MYC oncogene, 44
MYH-associated polyposis (MAP), 115–116, 216
cancer risks with, 115
clinical features of, 116
diagnostic criteria for, 115–116
family history for, 217
incidence of, 216
management of, 217, 218
resources for, 116
tumor types, 216–217
NAME syndrome. See Carney complex,
types I and II
National Cancer Institute (NCI), 291
National Comprehensive Cancer Network, 291
National Institutes of Health Consensus
Conference, NF2 criteria of, 120
National Society of Genetic Counselors
(NSGC), 411, 443
code of ethics of, 429
ethics committee of, 431
National Toxicology Agency, U.S.-based, 14
Native Americans, cancer rates among, 4, 5
neoplasms
defined, 27
major types of, 28
nervous system
syndromes associated with, 451
tumors of, 451
neuroblastoma (NB), familial, 116–117
cancer risks with, 116–117
clinical features of, 117
diagnostic criteria for, 117
resources for, 117
syndrome subtypes, 117
neuroectodermal tumors, 30
neuroendocrine tumors, 199
neurofibromatosis, type 1 (NF1), 118–119
cancer risks with, 118
critical features of, 119
diagnostic criteria for, 118–119
resources for, 119
neurofibromatosis, type 2 (NF2), 119–121
cancer risks with, 120
clinical features of, 121
diagnostic criteria for, 120–121
resources for, 121
nevoid basal cell carcinoma syndrome
(NBCCS), 121–123
cancer risks with, 121–122
clinical features of, 123
diagnostic criteria for, 122
resources for, 123
nipple, breast, 152, 152, 153
nonmaleficence, principle of, 414–415
nonpolyposis, hereditary, 213. See also Lynch
syndrome
nose
syndromes associated with, 457
tumors of, 457
NSAIDs, and polyp development, 211
nuclear transcription factors, 61
numbers, in risk communication, 278, 283
obesity
and breast cancer incidence, 157
in cancer etiology, 15
and CRC, 194
occupational exposures, in cancer etiology,
17–18, 17
oncogenes, 49
activation of, 62, 62–64, 64
general description of, 59–61, 60
hereditary cancer syndromes associated
with, 62
RET, 64, 64
oncologist, referral to, 26
osteochondromyxoma of bone, 88
osteosarcoma, 131
outcomes
in risk communication, 283
and risk perception, 276
ovarian cancer
in HBOCS, 172
monitoring for, 174
ovarian teratoma, 70
ovary
syndromes associated with, 458
tumors of, 458
overgrowth syndrome, 80
Paget’s disease of the breast, 160–161
pancreas
syndromes associated with, 455
tumors of, 455
papillary carcinoma, of breast, 161
papillomas, of breast, 158
Pap smear, 25
paraganglioma, subtype 1 (PGL1) syndrome,
125
paraganglioma-pheochromocytoma (PGL-
PCC) syndrome, 123–125
cancer risks with, 123–124
case history, 255–258, 257, 259
clinical features of, 124
diagnostic criteria for, 124
resources for, 125
syndrome subtypes for, 124–125
parathyroid gland
syndromes associated with, 454
tumors of, 454
pharynx
syndromes of, 450
tumors of, 450
Peutz-Jeghers syndrome (PJS), 125–127, 171,
180
cancer risks with, 126
clinical features of, 126–127
diagnostic criteria for, 126
family history assessment for, 181
management of, 181–182, 182
resources for, 127
tumor types, 180
parotid gland
syndromes associated with, 454
tumors of, 454
PNETs, 122
polychlorinated biphenyls (PCBs), cancers
associated with, 18
polyploidy, in oncogene activation,
17
polyposis. See also familial adenomatous
polyposis
adenomatous, 195
in FAP, 91
gastrointestinal, 180
polyps
adenomatous, 195, 217
CRC arising from, 194–195
FAP-related, 209
hamartomatous intestinal, 128
histologically confirmed hamartomatous, 126
hyperplastic, 196
inflammatory, 196
JPS-related, 211–212
juvenile, 98, 99, 196
in Lynch syndrome, 213
MAP-related, 216–217
positron emission tomography (PET) scan, of
breast, 165
posttraumatic stress disorder (PTSD), 362
poverty, and cancer risk, 7–8
predictive test, purpose of, 313. See also
genetic testing; test results
preferences, client, in risk communication, 284
preimplantation genetic diagnosis (PGD), 441–442
prenatal genetic testing, 441–442
preparation, for risk communication, 284–285
pressure/coercion for genetic testing, 432–433
presymptomatic test, purpose of, 313. See also
genetic testing; test results
prevalence, use of term, 2
Preventive Services Task Force, U.S., 162
principles, in bioethics, 410
privacy
autonomy and, 413–414, 414
respecting client, 422
PRKARIA gene test, 88
probability of developing cancer, in risk
assessment, 291, 293–294, 296
professional guidelines, 429, 430
professionalism, in psychosocial genetic
counseling, 388
professional organizations, ethics committees
of, 431
professional/societal issues in genetic
counseling, 443
progeria of adult, 139. See Werner syndrome
prognosis, in cancer history, 229
progression, of carcinogenesis, 54, 55
projection
in case example, 407
of client, 369–370
in genetic counseling, 389
proliferation, cell, 50, 50
promotion, of carcinogenesis, 53, 54
proportions, in risk communication, 279
prostate gland
syndromes associated with, 458
tumors of, 458
proto-oncogenes
functions of, 59
major types of, 60
provider-client relationship, 420
providers, for testing program, 318
pseudopolyp, 196
psychosocial assessment, features of, 379–382, 379–382
psychosocial factors, in cancer history, 232
psychosocial issues, exploring, 270
PTCH gene, 122
PTEN hamartoma syndrome (PHS), 127–130, 158, 171, 182
cancer risks with, 127–128
clinical features of, 129
diagnostic criteria for, 128–129
family history assessment for, 183
management of, 184, 184
resources for, 130
syndrome subtypes for, 129
tumor types, 182–183
PTEN mutations, 183
questionnaire, family history, 239
questions
about client’s reactions, 382
in construction of genogram, 392
about coping strategies, 382
for creating CEGRM, 394
in effective psychosocial genetic
counseling, 385–386
about emotional responses to cancer risk, 381
about emotional well-being, 379
for ethical dilemmas, 426–428
for family history, 232, 255–255
about mental health history, 380
in risk communication, 288
race, in cancer etiology, 12–13
radiation, in cancer etiology
ionizing, 16
ultraviolet, 16
radiation doses, 40
radiation exposure
and breast cancer incidence, 157–158
and CRC, 194
radiation therapy
aim of, 39
for breast cancer, 168–169, 170, 171
for CRC, 205
effectiveness of, 40
neoadjuvant, 206
side effects of, 40
rads, measurement of, 40
raloxifene, 169
ranges, in risk communication, 279
ras oncogene, 59
rate, use of term, 2
rationale, clients’, in psychosocial genetic counseling, 386
ratios, in risk communication, 280
RB gene, 57
RB1 gene, 132
reassurance, in risk communication, 286
rectum. See also colorectal cancer
anatomy of, 187–191, 188, 189, 190
syndromes associated with, 454
tumors of, 454
referrals
making, 270
mental health, 394–398, 396, 397
to oncologist, 26
relationship lines, in pedigree, 461, 462
relationships, on genogram, 393
relative risk, use of term, 2
relatives. See also family members
in cancer history, 231
cancer in, 228
communication with, 378
estranged, 243–244
false information provided by, 246
lost, 243
with related cancers, 246–247
testing, 310
and test results, 342–343
relief, for cancer counseling clients, 361
religion, and genetic testing, 324
renal pelvis
syndromes associated with, 460
tumors of, 460
reproductive system
PJS-related cancers of, 181
syndromes associated with, 457–458
tumors of, 457–458
research, pedigrees in, 225
research laboratories, 316
research treatment trials, 33
resiliency, feelings of, 361
resistant clients, in psychosocial genetic counseling, 387
resources
justice and, 416
providing client with, 289
respectfulness, of genetic counselors, 419
respiratory system
syndromes of, 450
tumors of, 450
results, of genetic tests, 319. See also
disclosure; test results
retinoblastoma (RB), hereditary, 131–133, 252,
252
cancer risks with, 131
clinical features of, 132
diagnostic criteria for, 131–132
resources for, 133
syndrome subtypes for, 132
retinoblastoma (RB), Knudson’s model of, 57, 58
retinoid agents, 45
RET oncogene, 64, 64, 114
rights
in bioethics, 410
of family members, competing, 439
risk
absolute, 282
categories for, 251–255
defined, 273
justice and, 416
personalized, 280–281
uncertain, 255
risk assessment
of clients
at high risk, 295–298, 296
at low risk, 289–292, 290
at moderate risk, 292, 292–295, 293
in counseling session, 269
counseling visit for, 271, 272
risk communication, 267
in counseling session, 269
defined, 284
effective strategies for, 284–289, 285
goal of, 273
presenting information in, 278–281, 279
strategies for effective, 281, 281–289, 285
risk factors, 10–11, 11, 12, 231
modifiable risk factors, 12, 13–18, 14, 16, 17
nonmodifiable risk factors, 11–13, 12
risk information, strategies for presenting, 281, 281–289, 285
risk perception, 274, 274–278
and cancer-related fears, 374
genetic counseling and, 267–271
Rothmund-Thomson syndrome (RTS), 133–134
cancer risks with, 133
clinical features of, 134
diagnostic criteria for, 133–134
resources for, 134
RPS19 gene test, 89
rules, in bioethics, 410

sadness, client’s, 361–362
Safer v. Estate of Pack, 437–438
sarcomas
of breast, 161
defined, 29
LFS-related, 178
by organ system, 29
schwannomas, 120
scoliosis, and Hodgkin’s disease, 157–158
screening
ACS breast cancer guidelines for, 162, 162
in cancer history, 230
for colon cancer, 200, 200
purpose of, 313–314
scrotal cancer, in chimney sweeps, 10
SDHB mutation, 123, 125
SDHC gene mutation, 125
SDHD gene, 71
sedentary lifestyle
and breast cancer incidence, 157
in cancer etiology, 15
segmental resection, for CRC, 204
self-breast examination (SBE), 163
sensitive genetic information, 436
serosa, of colorectal walls, 189, 190
Sertoli cell tumors, 181
sex cord tumors with annular tubules (SCTAT), 126, 181
shame, 360–361
sigmoid colon, anatomy of, 188, 188
sigmoidoscopy, 199, 201
signaling systems, of cancer cells, 52
signal transducers, 61
signet ring adenocarcinoma of stomach, 175
signet ring cell carcinoma, 198
single-site analysis, in pretest counseling, 327
sinus
syndromes associated with, 457
tumors of, 457
Sipple syndrome. See multiple endocrine neoplasia, type 2
sister chromatid exchanges (SCE), in Bloom syndrome, 82–83
site of origin, 27
skin
of breast, 153
in Lynch syndrome, 214
melanoma of, 11–12
syndromes associated with, 458
tumors of, 458–459
in xeroderma pigmentosum, 144
skin lesions, PHS-related, 183
SMAD4 mutations, 98, 99
small intestine
syndromes associated with, 455
tumors of, 455
societal/professional issues in genetic counseling, 443
soft tissue
syndromes associated with, 453
tumors of, 453
southern blotting, 36
spinal cord
syndromes associated with, 451
tumors of, 451
spirituality, and risk perception, 277–278
spleen
syndromes associated with, 455
tumors of, 455
squamous cell (epidermoid) carcinoma, 198
staging
for breast cancer, 166, 167
clinical, 33–35, 35
for CRC, 203, 204, 206–207
state licensing boards, 411
statistics, cancer
cancer-related mortality, 5–8, 5–7
global incidence, 8–10, 8–10
incidence in U.S., 2–5, 3, 4, 4
terminology used in, 1–2
stem cells
sources of, 43
transplantation, 42–43
stomach. See also gastrointestinal system
syndromes associated with, 455
tumors of, 455
stomach cancer, HDGC-related, 175
stool DNA (sDNA) test, 202
stool guaiac test, for CRC, 202
stories
  family, 226
  response to client’s, 233–234, 236
stress
  client response to, 362
  test results and, 342
stressors, on genogram assessment tool, 392
submucosa, of colorectal walls, 189, 190
suicidal ideation, and ethical decision making, 415, 438
sun exposure, and melanoma, 110
support, pedigree indicating level of, 225–226
support groups, cancer risk, 398–400
support network, in psychological assessment, 336
surgery
  for breast cancer, 168, 170, 171
  for catheter placement, 39
  conservative, 39
  for CRC, 204–205
  exploratory, 38
  palliative, 39
  radical, 38
surveillance practices, in cancer history, 230
survival rates, 6–8, 7
TACSTD1 gene, 351–352
tamoxifen, 169
team of providers, for testing program, 318
teeth
  syndromes associated with, 457
tumors of, 457
telangiectases, 76
teratomas, 30
testes
  syndromes associated with, 458
tumors of, 458
testing. See genetic testing
test results
  adjustment to, 345
  anticipated impact of, 336
  client’s family and, 344–345
  for clients with children, 343
  for deceased clients, ownership of, 439–440
  and follow-up interactions, 345
  implications of, 343–344
  indeterminate negative, 341
  intermediate negative, 325–326, 328, 329
  negative, 329–330, 332
  omitting from medical record, 435
  positive, 325, 328, 329, 341
  referrals to specialists following, 346
  and review of genetics, 345
  true negative, 328, 329, 341–342
  uncertain, 329
  undisclosed, dispensation of, 435–436
  unexpected, 343
  variant of uncertain significance, 326–327
  variant result, 348–349
  VUS, 342
13q deletion syndrome, 132
thyroid cancers
  PHS-related, 183
  screening for, 185
thyroid gland
  syndromes associated with, 454
tumors of, 454
timing
  in psychosocial assessment, 381
  in risk communication, 288–289
tissue type, embryonic origins of, 27, 27
TNM staging system, 34–35, 35
  for breast cancer, 167
  for CRC, 204
tobacco exposure, in cancer incidence, 11, 11
  tobacco use
    in cancer etiology, 14–15
    and CRC, 194
TP53 mutations, 102, 104, 177, 178, 441
TP53 testing, 103, 353, 354, 355, 441
TP53 tumor suppressor gene, 44
trans-acting factors, loss of, 73
transference, in genetic counseling, 388
transitional cell carcinomas, 30
translocations, in oncogene activation, 62–63
transplant, autologous vs. allogenic, 43
transverse colon, anatomy of, 188, 188
trauma, 362
treatment, cancer, 37–38
  in cancer history, 229
  chemotherapy, 41–42
  cryotherapy, 44
  laser therapy, 44
  radiation therapy, 39–40
  stem cell transplantation, 42–43
  surgery, 38–39
trustworthiness, of genetic counselors, 419
truth telling, 423
TS gene, 136
tuberous sclerosis complex (TSC), 81, 134–136
cancer risks with, 134–135
clinical features of, 136
diagnostic criteria for, 135–136
resources for, 136
syndrome subtypes for, 136
tuberous sclerosis (TS)/polycystic kidney disease (PKD) contiguous gene syndrome, 136
tubular carcinoma, of breast, 160
tumor grading
for breast cancer, 166
for CRC, 203
tumor markers, commonly ordered, 26, 26
tumors
benign, 31–32
classification of
benign or malignant, 31–32
clinical staging for, 33–35, 35
grading for, 32–33
genetic analysis of, 35
chromosome studies, 36
molecular studies, 36, 37
metastatic, 54, 55, 56, 57, 57
neuroectodermal, 30
neuroendocrine, 199
precancerous, 32
tumor suppressor genes, 49, 64
categories of, 65–66, 66
general description of, 65
hereditary cancer syndromes associated with, 66
inactivation of, 66–67
mismatch repair genes, 68–70, 69
TP53 gene, 67–68, 68
Turcot syndrome, 208. See also familial adenomatous polyposis
Turker syndrome, cancer associated with, 13
two-hit theory, of cancer development, 57

unilateral disomy (UPD), 71
urinary tract
syndromes associated with, 460
tumors of, 460
urogenital system, syndromes associated with, 460
uterus
in Lynch syndrome, 213
PHS-related tumors of, 183
syndromes associated with, 458
tumors of, 458

values, in bioethics, 410
variant of uncertain significance (VUS), 326–327
veracity, of genetic counselors, 420
verbal confirmation, of cancer history, 240
viral insertion, in oncogene activation, 63
virtues, in bioethics, 410
viruses
in cancer history, 231
carcinogenicity of, 15–16, 16
Vogelstein’s model, of colon cancer, 58, 58–59
Von Hippel-Lindau (VHL) syndrome, 137–139
cancer risks with, 137
clinical features of, 138
diagnostic criteria for, 137–138
pedigree of family at risk for, 253, 253
resources for, 139
syndrome subtypes for, 138–139
Von Recklinghausen disease. See neurofibromatosis, type 1
vulva
syndromes associated with, 458
tumors of, 458

WAGR syndrome, 142. See also Wilms tumor
warning signs, of breast cancer, 163, 163
wedge resection, for CRC, 204
well-being, and interest in testing, 323
Wermer syndrome. See multiple endocrine neoplasia, type 1
Werner syndrome, 139–141
cancer risks with, 139
case example, 405–407
case history, 255–258, 257, 259
clinical features of, 138
diagnostic criteria for, 137–138
resources for, 141
Wilms tumor, 30, 79, 141–143
cancer risks with, 141
clinical features of, 142
Wilms tumor (cont’d)
- diagnostic criteria for, 141–142
- resources for, 143
- syndrome subtypes, 142
- wisdom, of genetic counselors, 420
- word choices, in risk communication, 285–286
- workup, for cancer, 25
- WT2 gene, 142

xeroderma pigmentosum (XP), 143–145
- cancer risks with, 143
- clinical features of, 144
- diagnostic criteria for, 143–144
- resources for, 145
- syndrome subtypes for, 144–145
- XP/CS complex, 144–145
- XP genes, 144
- XP/trichothiodystrophy (TDD) syndrome, 145
- XP variant, 145
- X-ray studies
  - in CRC, 203
  - double contrast barium enema, 202
- Zollinger-Ellison syndrome, 113